Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells.

Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells.

The human hepatocellular carcinoma (HCC) represents biologically aggressive and chemo-resistant cancers. Owing to the low affinity with the apoptotic factor Mcl-1, the BH3 mimetic drug ABT-737 failed to exert potent cancer-killing activities in variety of cancer models including HCC. The current stu...

Full description

Bibliographic Details
Main Authors:	Hong Zhu, Wei Yang, Ling-juan He, Wan-jing Ding, Lin Zheng, Si-da Liao, Ping Huang, Wei Lu, Qiao-jun He, Bo Yang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2012-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3527540?pdf=render

Similar Items

Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma.
by: Karianne Risberg, et al.
Published: (2011-01-01)

ABT-737 synergizes with Bortezomib to kill melanoma cells
by: Steven N. Reuland, et al.
Published: (2012-02-01)

Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1
by: Zantl Niko, et al.
Published: (2010-06-01)

Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia
by: Wu X, et al.
Published: (2017-10-01)

Exploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomas
by: Jain, H, et al.
Published: (2012)

Exploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomas.
by: Harsh Vardhan Jain, et al.
Published: (2014-01-01)

Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia [Corrigendum]
by: Wu X, et al.
Published: (2018-01-01)

Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors.
by: Xin Yu, et al.
Published: (2019-01-01)

Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.
by: Fitzgerald, D, et al.
Published: (2011)

Melatonin Can Modulate the Effect of Navitoclax (ABT-737) in HL-60 Cells
by: Alexey Lomovsky, et al.
Published: (2020-11-01)

ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL
by: Li Ji-Yu, et al.
Published: (2012-12-01)

Rational Formulation of targeted ABT-737 nanoparticles by self-assembled polypeptides and designed peptides
by: Polina Aibinder, et al.
Published: (2024-02-01)

The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma
by: Fuchs Jörg, et al.
Published: (2011-08-01)

Rapid detection of an ABT-737-sensitive primed for death state in cells using microplate-based respirometry.
by: Pascaline Clerc, et al.
Published: (2012-01-01)

The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.
by: Steven N Reuland, et al.
Published: (2011-01-01)

Aspirin Induced Glioma Apoptosis through Noxa Upregulation
by: Cheng-Yi Chang, et al.
Published: (2020-06-01)

The inhibition of Beclin1-dependent autophagy sensitizes PTC cells to ABT737-induced death
by: Ning Hu, et al.
Published: (2024-03-01)

Curcumin at Low Doses Potentiates and at High Doses Inhibits ABT-737-Induced Platelet Apoptosis
by: Natalia Rukoyatkina, et al.
Published: (2021-05-01)

The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
by: Denis V. Baev, et al.
Published: (2014-01-01)

Comparison of putative BH3 mimetics AT-101, HA14-1, sabutoclax and TW-37 with ABT-737 in platelets
by: Hao Wei, et al.
Published: (2021-01-01)

Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells.
by: Manoj K Pandey, et al.
Published: (2013-01-01)

ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer
by: Eun Young Kim, et al.
Published: (2017-04-01)

Synergistic co-delivery of diacid metabolite of norcantharidin and ABT-737 based on folate-modified lipid bilayer-coated mesoporous silica nanoparticle against hepatic carcinoma
by: Minchen Liu, et al.
Published: (2020-08-01)

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
by: Sandra Weller, et al.
Published: (2022-04-01)

BCL2L10 Is Overexpressed in Melanoma Downstream of STAT3 and Promotes Cisplatin and ABT-737 Resistance
by: María Josefina Quezada, et al.
Published: (2020-12-01)

Celastrol Inhibited Human Esophageal Cancer by Activating DR5-Dependent Extrinsic and Noxa/Bim-Dependent Intrinsic Apoptosis
by: Xihui Chen, et al.
Published: (2022-06-01)

The Application of Arsenic Trioxide in Ameliorating ABT-737 Target Therapy on Uterine Cervical Cancer Cells through Unique Pathways in Cell Death
by: I-Lun Hsin, et al.
Published: (2019-12-01)

B-cell lymphoma 2 inhibitor ABT-737 induces Beclin1- and reactive oxygen species-dependent autophagy in Adriamycin-resistant human hepatocellular carcinoma cells
by: Xiaoxiao Yao, et al.
Published: (2017-03-01)

The BCL‐2 family protein inhibitor ABT‐737 as an additional tool for the treatment of EBV‐associated post‐transplant lymphoproliferative disorders
by: Aude Robert, et al.
Published: (2020-10-01)

RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway.
by: Angela M Keuling, et al.
Published: (2009-01-01)

ABT-263 exerts a protective effect on upper urinary tract damage by alleviating neurogenic bladder fibrosis
by: Yibo Wen, et al.
Published: (2023-12-01)

Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization.
by: Nelly Buron, et al.
Published: (2010-03-01)

Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner
by: Irina Kiprianova, et al.
Published: (2015-07-01)

Upregulation of NOXA by 10-Hydroxycamptothecin plays a key role in inducing fibroblasts apoptosis and reducing epidural fibrosis
by: Jihang Dai, et al.
Published: (2017-01-01)

Noxa caput sequitur
by: Sirks, A
Published: (2013)

ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells
by: Ricardo Parrondo, et al.
Published: (2013-09-01)

BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-737
by: Danielle S. Potter, et al.
Published: (2014-02-01)

BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?
by: Sachiko Kawashima-Goto, et al.
Published: (2015-01-01)

Induction of the ER stress response in NRVMs is linked to cardiotoxicity caused by celastrol
by: Chen Zhong, et al.
Published: (2022-08-01)

Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms
by: Tri Nguyen, et al.
Published: (2018-11-01)